Vanda Pharmaceuticals Inc. (VNDA) stock
Close on Nov 17, 2026Market cap $230.39MP/E –Yield –
Vanda Pharmaceuticals Inc. grew revenue 8.1% to $229.28M over the twelve months to Sep 30, 2026. Free cash flow was -$139.96M. At the latest close the market valued the company at $230.39M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $230.39M
- P/E ratio
- –
- Price to sales
- 1.00
- Price to book
- 1.15
- Dividend yield
- –
- Free cash flow yield
- -60.75%
Fundamentals
- Revenue
- $229.28M
- Net income
- -$274.83M
- EPS, diluted
- -$4.62
- Free cash flow
- -$139.96M
- Book value per share
- $3.31
- Diluted shares
- 60M
Trading
- Next earnings
- Feb 10, 2027 (estimated, after the close)
- Previous close
- $3.81
- Open
- $3.81
- Day's range
- $3.78 – $3.90
- Volume
- 830,314
- Average volume (20 days)
- 1,313,199
- Index membership
- Russell 2000, Russell 3000
- 52-week range
- $3.56 – $9.94
- RSI (14 days)
- 40.6
- Volatility (1 year)
- 80.5%
- Relative volume
- 0.81×
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | VNDA | S&P 500 | Difference | VNDA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.5% | -4.0% | −1.4 pts | ||
| 3 months | -27.6% | -5.0% | −22.6 pts | ||
| Year to date | -56.8% | +8.2% | −65.1 pts | ||
| 1 year | -13.4% | +11.2% | −24.6 pts | ||
| 3 years | +7.3% | +68.5% | −61.2 pts | +2.4% | +19.0% |
| 5 years | -78.5% | +67.3% | −145.8 pts | -26.5% | +10.8% |
| 10 years | -77.7% | +291.6% | −369.3 pts | -13.9% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vanda Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- News
About Vanda Pharmaceuticals
Pharmaceutical Preparations
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders and other medical conditions. Its commercial product lineup includes Fanapt for schizophrenia and bipolar I disorder, Hetlioz for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome sleep disturbances, Ponvory for relapsing forms of multiple sclerosis, and Nereus for motion-induced vomiting. The company operates in a product segment and distributes its medications primarily to wholesale drug distributors and specialty pharmacies.
Company profile, executives and historyVanda Pharmaceuticals stock: common questions
What is Vanda Pharmaceuticals's stock price?
VNDA closed at $3.81 on Nov 17, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $3.56 and $9.94.
What is Vanda Pharmaceuticals's market cap?
Vanda Pharmaceuticals was worth $230.39M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is VNDA's P/E ratio?
Vanda Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.62), so it has no meaningful P/E ratio.
How much revenue does Vanda Pharmaceuticals make?
Vanda Pharmaceuticals reported revenue of $229.28M for the twelve months to Sep 30, 2026, up 8.1% from a year earlier.
Does Vanda Pharmaceuticals pay a dividend?
No. Vanda Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Vanda Pharmaceuticals report earnings next?
Vanda Pharmaceuticals is expected to report Q4 FY2026 results on Feb 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has VNDA stock performed over the past year?
Including dividends, VNDA returned -13.4% over the past year, against +11.2% for the S&P 500.
How many VNDA shares are sold short?
8M shares were sold short at the latest FINRA report, 13.89% of the float, or 5.9 days of average trading volume.
Who are Vanda Pharmaceuticals's competitors?
Companies most similar to Vanda Pharmaceuticals by business, industry and size include AXSM, SNDX, XERS, AMRN, ZVRA.
See a number that looks wrong?